Systematic review finds GLP‐1 receptor agonists improve weight and metabolic disease outcomes in patients with inflammatory bowel disease, suggesting safety for use.
Key Points
GLP‐1 receptor agonists improved weight loss in patients with inflammatory bowel disease, notably enhancing metabolic disease.
Incorporating results from 14 studies, significant reductions in body weight and improved metabolic parameters were reported, including reduced hemoglobin A1c.
Observational analyses revealed that GLP‐1 receptor agonists did not increase safety risks related to inflammatory bowel disease exacerbations or adverse events.
Findings may support wider use of GLP‐1 receptor agonists in managing metabolic disease within the inflammatory bowel disease population.